Biotechnology Belgium’s privately-held biotech Novadip Biosciences today announced that the US Food and Drug Administration has granted Rare Pediatric Disease designation and Orphan Drug designation for NVD 003, a cell therapy for the treatment of congenital pseudarthrosis of the tibia (CPT), a rare but serious and debilitating condition, that primarily affects children with devastating consequences. 23 December 2020